Pfizer to settle Celebrex and Bextra suits for $894 million
[C#198600199:Pfizer]has agreed in principle to pay $894 million to resolve most legal claims surrounding its COX-2 inhibitors, Celebrex (celecoxib) and Bextra (valdecoxib).
[C#198600199:Pfizer]has agreed in principle to pay $894 million to resolve most legal claims surrounding its COX-2 inhibitors, Celebrex (celecoxib) and Bextra (valdecoxib).